Adebrelimab with chemotherapy after HIFU for breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a new treatment for a type of breast cancer that is hormone receptor-positive (HR+) and HER2-negative. The treatment combines a drug called adebrelimab with chemotherapy, given after a procedure called HIFU (high-intensity focused ultrasound) that uses sound waves to heat and destroy cancer cells. The goal is to see if this combination can improve outcomes before surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 or older.
- Your breast cancer is hormone receptor-positive (HR+) and HER2-negative.
- Your tumor is at least 3 cm in size and has a high grade (grade 3), meaning it looks aggressive under a microscope.
- Your cancer has not spread to distant parts of the body (no metastasis).
- You have not had other cancer treatments for this breast cancer before, and you are not pregnant or breastfeeding.
- Your overall health is good (able to perform daily activities, no major heart or organ problems).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of an immunotherapy drug (adebrelimab) plus chemotherapy before surgery for people with high-risk, hormone receptor-positive, HER2-negative breast cancer. The goal is to see if this approach can shrink tumors more effectively than chemotherapy alone.
This trial tests a combination of a new immunotherapy drug (adebrelimab) with a targeted pill (dalpiciclib) and standard hormone therapy for women with advanced hormone receptor positive, HER2 negative breast cancer. It may help patients who have not yet had certain prior treatments, aiming to slow the cancer's growth.
This study tests a new combination treatment for people with advanced HER2-negative breast cancer. It uses an immunotherapy drug (PD-L1 inhibitor) with radiation therapy, and sometimes a supplement called ursodeoxycholic acid, to see if it helps control the cancer.
This trial tests combining stereotactic radiation therapy with immunotherapy (adebrelimab) and chemotherapy (nab-paclitaxel and carboplatin) before surgery for early or locally advanced triple-negative breast cancer. The goal is to see if this combination improves treatment response.
This trial tests a new drug combination given before surgery for early-stage, hormone receptor-positive breast cancer. It aims to see if this approach can improve outcomes for patients with high-risk features.
This trial tests adding a drug called adebrelimab to standard chemotherapy and possibly radiation, given before surgery for breast cancer that is HER2-negative and locally advanced. The goal is to see if this combination helps shrink tumors more effectively, potentially allowing for breast-conserving surgery.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.